Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 2/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.43 |
| ▸ | FNTA | P49354 | 2/20 | 0.42 |
| ▸ | FNTB | P49356 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | NLRP1 | Q9C000 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.39 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170593 | 0.83 | KMT2A (0.45) | PPARGPPARAFFAR1KMT2A | |
| SCHEMBL4187187 | 0.82 | LDHA (0.55) | L3MBTL1PPARGPPARAFFAR1FNTA | |
| SCHEMBL4173523 | 0.82 | PPARG (0.50) | PPARGPPARALMNAKMT2AMEN1 | |
| SCHEMBL4180718 | 0.82 | PPARG (0.47) | PPARGPPARAFFAR1FNTAFNTB | |
| SCHEMBL4183100 | 0.82 | RXRA (0.39) | L3MBTL1FFAR1KMT2APOLB | |
| SCHEMBL9236830 | 0.80 | PPARG (0.43) | L3MBTL1PPARGPPARAFFAR1FNTA | |
| SCHEMBL9236828 | 0.80 | PPARG (0.43) | L3MBTL1PPARGPPARAFFAR1FNTA | |
| SCHEMBL23606001 | 0.80 | L3MBTL1 (0.49) | L3MBTL1PPARGPPARAFFAR1FNTA | |
| SCHEMBL4567678 | 0.79 | PPARG (0.59) | L3MBTL1PPARGPPARA | |
| SCHEMBL10550130 | 0.75 | ACHE (0.41) | PPARGPPARALMNAKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | claimed |
| EP-1951655-A2 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-08-06 | — | — | EP | claimed |
| WO-2007057767-A2 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | claimed |
| US-20090227680-A1 | Amino Acid Derivatives | PFIZER, INC. (US) | 2009-09-10 | — | — | US | disclosed |
| EP-1951655-A2 | AMINO ACID DERIVATIVES | Pfizer Limited (GB) | 2008-08-06 | — | — | EP | disclosed |
| WO-2007057767-A2 | AMINO ACID DERIVATIVES | PFIZER LIMITED (GB) | 2007-05-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227680-A1 | Amino Acid Derivatives | OPRL1, OPRK1, AVPR1A | L3MBTL1 2098/4885PPARG 2322/4885PPARA 1589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.